4//SEC Filing
PROTEON THERAPEUTICS INC 4
Accession 0001104659-14-074934
$TARACIK 0001359931operating
Filed
Oct 28, 8:00 PM ET
Accepted
Oct 29, 6:38 PM ET
Size
13.7 KB
Accession
0001104659-14-074934
Insider Transaction Report
Form 4
Haines Timothy
Director10% Owner
Transactions
- Purchase
Common Stock
2014-10-27$10.00/sh+950,000$9,500,000→ 950,000 total(indirect: By Abingworth Bioventures VI, LP) - Conversion
Common Stock
2014-10-27+1,067,872→ 2,017,872 total(indirect: By Abingworth Bioventures VI, LP) - Conversion
Series D Convertible Preferred Stock
2014-10-27−16,044,081→ 0 total(indirect: By Abingworth Bioventures VI, LP)→ Common Stock (1,010,969 underlying) - Other
Option (Right to Purchase)
2014-10-27−12,835,264→ 0 total(indirect: By Abingworth Bioventures VI, LP)→ Series D Convertible Preferred Stock (808,775 underlying)
Footnotes (6)
- [F1]These shares were purchased in connection with the Issuer's initial public offering of Common Stock.
- [F2]The shares are held by Abingworth Bioventures VI, LP ("Abingworth"). Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The reporting person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
- [F3]This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- [F4]Upon the closing of the Issuer's initial public offering, each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a one-for-one basis (without payment of further consideration and with no expiration date) plus an additional 56,903 incremental shares as a result of an adjustment as provided for in the Company's certificate of incorporation.
- [F5]Reflects a 1-for-15.87 reverse stock split effected on October 6, 2014.
- [F6]Abingworth had a right to purchase shares of Series D Convertible Preferred Stock under the Series D Purchase Agreement at a price of $0.588656, which right to purchase ceased to be exercisable upon the initial filing of the Issuer's registration statement for its initial public offering, and terminated upon the completion of the Issuer's initial public offering of Common Stock. Each share of Series D Preferred Stock issuable upon exercise of the right to purchase would have been convertible into shares of the Issuer's common stock as described in footnote (3) above.
Documents
Issuer
PROTEON THERAPEUTICS INC
CIK 0001359931
Entity typeoperating
Related Parties
1- filerCIK 0001359931
Filing Metadata
- Form type
- 4
- Filed
- Oct 28, 8:00 PM ET
- Accepted
- Oct 29, 6:38 PM ET
- Size
- 13.7 KB